Sinovac Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Sinovac Biotech
SVA Stock  USD 6.47  0.00  0.00%   
Sinovac Biotech's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Sinovac Biotech's valuation are provided below:
Gross Profit
443.4 M
Profit Margin
0.2161
Market Capitalization
642.4 M
Enterprise Value Revenue
0.0309
Revenue
510.6 M
We have found one hundred twenty available fundamental trend indicators for Sinovac Biotech, which can be analyzed and compared to other ratios and to its competition. All investors should make sure to double-check all of Sinovac Biotech current market performance against the performance between 2010 and 2026 to make sure the company can sustain itself down the road. The current year's Market Cap is expected to grow to about 609 M, whereas Enterprise Value is forecasted to decline to (394.5 M).

Sinovac Biotech Total Revenue

1.02 Billion

Check Sinovac Biotech financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Sinovac Biotech's main balance sheet or income statement drivers, such as Interest Expense of 2.7 M, Other Operating Expenses of 1.2 B or Total Operating Expenses of 982.3 M, as well as many indicators such as Price To Sales Ratio of 1.57, Dividend Yield of 0.51 or PTB Ratio of 0.0808. Sinovac financial statements analysis is a perfect complement when working with Sinovac Biotech Valuation or Volatility modules.
  
Build AI portfolio with Sinovac Stock
Check out the analysis of Sinovac Biotech Correlation against competitors.
For information on how to trade Sinovac Stock refer to our How to Trade Sinovac Stock guide.

Sinovac Biotech Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets16.5 B15.7 B5.6 B
Slightly volatile
Other Current Liabilities1.2 B1.1 B481.5 M
Slightly volatile
Total Current Liabilities1.4 B1.3 B571.8 M
Slightly volatile
Total Stockholder Equity10.5 B10 B3.4 B
Slightly volatile
Cash850.2 M1.5 B1.3 B
Slightly volatile
Cash And Short Term Investments13.6 B12.9 B4.5 B
Slightly volatile
Common Stock Shares Outstanding57.9 M114.5 M75.6 M
Slightly volatile
Liabilities And Stockholders Equity16.5 B15.7 B5.6 B
Slightly volatile
Other Stockholder Equity653.6 M622.4 M302.8 M
Slightly volatile
Total Liabilities2 B1.9 B760.7 M
Slightly volatile
Total Current Assets14.3 B13.6 B4.8 B
Slightly volatile
Common Stock58.1 K115 K73.1 K
Slightly volatile
Short and Long Term Debt Total361 M343.8 M116.1 M
Slightly volatile
Property Plant And Equipment Net1.2 B1.2 B452.7 M
Slightly volatile
Accounts Payable20.9 M19.9 M12.7 M
Slightly volatile
Non Current Assets Total2.2 B2.1 B757.6 M
Slightly volatile
Other Assets1.091.158.9 M
Very volatile
Long Term Debt214.7 M204.5 M54.6 M
Slightly volatile
Net Receivables544.2 M518.3 M248.4 M
Slightly volatile
Non Current Liabilities Total588.4 M560.4 M188.9 M
Slightly volatile
Other Current Assets13.2 M19.3 M19.2 M
Slightly volatile
Short Term Debt98.9 M94.2 M35.9 M
Slightly volatile
Property Plant Equipment343.2 M326.8 M161.3 M
Slightly volatile
Current Deferred Revenue31.6 M23.1 M37.8 M
Pretty Stable
Inventory168.9 M160.9 M83.8 M
Slightly volatile
Property Plant And Equipment Gross1.8 B1.7 B576.5 M
Slightly volatile
Intangible Assets11.6 M9.8 M14.7 M
Slightly volatile
Common Stock Total Equity70.2 K89.1 K88 K
Very volatile
Other Liabilities10.1 M9 M9.1 M
Pretty Stable
Short and Long Term Debt71.9 M68.5 M35.9 M
Slightly volatile
Net Tangible Assets899.6 M856.7 M415 M
Slightly volatile
Long Term Debt Total1.6 M1.7 M2.9 M
Pretty Stable
Capital Surpluse157.5 M239.2 M160.5 M
Slightly volatile
Net Invested Capital10.8 B10.3 B3.5 B
Slightly volatile
Net Working Capital12.9 B12.3 B4.3 B
Slightly volatile
Capital Stock126.1 K132.2 K116 K
Slightly volatile

Sinovac Biotech Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Interest Expense2.7 M2.6 M1.8 M
Slightly volatile
Other Operating Expenses1.2 B1.1 B545.5 M
Slightly volatile
Total Operating Expenses982.3 M935.5 M380.3 M
Slightly volatile
Depreciation And Amortization174.8 M166.5 M55.8 M
Slightly volatile
Total Revenue1 B515.5 M1.5 B
Pretty Stable
Cost Of Revenue219.2 M208.7 M165.3 M
Slightly volatile
Selling General Administrative563.1 M536.3 M242.8 M
Slightly volatile
Selling And Marketing Expenses3.2 M3 M1.6 M
Slightly volatile
Research Development416 M396.2 M134.2 M
Slightly volatile
Interest Income102.8 M97.9 M39.7 M
Slightly volatile
Reconciled Depreciation174.8 M166.5 M54.5 M
Slightly volatile

Sinovac Biotech Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow5.2 B4.9 B1.9 B
Slightly volatile
Depreciation174.8 M166.5 M54.6 M
Slightly volatile
Capital Expenditures175.9 M167.5 M116.4 M
Slightly volatile
End Period Cash Flow854.6 M1.5 B1.3 B
Slightly volatile
Change To Netincome99.1 M94.4 M38.8 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio1.571.652.3 K
Slightly volatile
Dividend Yield0.510.462.0302
Slightly volatile
PTB Ratio0.08080.085178.8841
Slightly volatile
Days Sales Outstanding347330197
Slightly volatile
Book Value Per Share11410945.241
Slightly volatile
Average Payables1.7 M2.3 M2.4 M
Pretty Stable
Stock Based Compensation To Revenue3.0E-44.0E-40.0071
Pretty Stable
Capex To Depreciation0.860.914.207
Very volatile
PB Ratio0.08080.085178.8841
Slightly volatile
Inventory Turnover1.941.491.5749
Pretty Stable
Days Of Inventory On Hand210253285
Pretty Stable
Payables Turnover5.799.458.928
Slightly volatile
Sales General And Administrative To Revenue0.980.940.6278
Slightly volatile
Average Inventory10.9 M10.3 M10.8 M
Slightly volatile
Research And Ddevelopement To Revenue0.730.690.2863
Slightly volatile
Capex To Revenue0.360.372.1762
Slightly volatile
Cash Per Share10610141.7749
Slightly volatile
Days Payables Outstanding37.9939.98596
Slightly volatile
Intangibles To Total Assets7.0E-47.0E-40.0295
Slightly volatile
Current Ratio9.749.285.5652
Slightly volatile
Tangible Book Value Per Share11410945.0655
Slightly volatile
Receivables Turnover1.091.144.796
Slightly volatile
Shareholders Equity Per Share82.6378.6932.3711
Slightly volatile
Capex Per Share1.381.321.1656
Slightly volatile
Graham Net Net94.8390.3236.6083
Slightly volatile
Average Receivables11.6 M18.6 M18.8 M
Pretty Stable
Revenue Per Share8.054.0514.8465
Pretty Stable
Interest Debt Per Share2.862.721.228
Slightly volatile
Debt To Assets0.02390.02520.2165
Slightly volatile
Graham Number41.0843.2441.6717
Slightly volatile
Operating Cycle333583449
Slightly volatile
Price Book Value Ratio0.08080.085178.8841
Slightly volatile
Days Of Payables Outstanding37.9939.98596
Slightly volatile
Company Equity Multiplier1.31.411.6816
Pretty Stable
Long Term Debt To Capitalization0.02190.0230.2835
Slightly volatile
Total Debt To Capitalization0.03630.03820.3479
Slightly volatile
Quick Ratio9.629.175.3577
Slightly volatile
Cash Ratio1.461.02.3009
Slightly volatile
Days Of Inventory Outstanding210253285
Pretty Stable
Days Of Sales Outstanding347330197
Slightly volatile
Price To Book Ratio0.08080.085178.8841
Slightly volatile
Fixed Asset Turnover0.470.52.1573
Pretty Stable
Debt Ratio0.02390.02520.2165
Slightly volatile
Price Sales Ratio1.571.652.3 K
Slightly volatile
Asset Turnover0.03590.03770.3036
Very volatile
Gross Profit Margin0.560.540.6901
Very volatile
Price Fair Value0.08080.085178.8841
Slightly volatile

Sinovac Biotech Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap609 M580 M470.8 M
Slightly volatile

Sinovac Fundamental Market Drivers

About Sinovac Biotech Financial Statements

Sinovac Biotech stakeholders use historical fundamental indicators, such as Sinovac Biotech's revenue or net income, to determine how well the company is positioned to perform in the future. Although Sinovac Biotech investors may analyze each financial statement separately, they are all interrelated. For example, changes in Sinovac Biotech's assets and liabilities are reflected in the revenues and expenses on Sinovac Biotech's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Sinovac Biotech. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue23.1 M31.6 M
Total Revenue515.5 M1 B
Cost Of Revenue208.7 M219.2 M
Sales General And Administrative To Revenue 0.94  0.98 
Research And Ddevelopement To Revenue 0.69  0.73 
Capex To Revenue 0.37  0.36 
Revenue Per Share 4.05  8.05 
Ebit Per Revenue(1.10)(1.15)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
FSLYFastly Class A
MOBMobilicom Limited American
CMGChipotle Mexican Grill
When determining whether Sinovac Biotech offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Sinovac Biotech's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Sinovac Biotech Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Sinovac Biotech Stock:
How To Invest In Sinovac
Details
Is Sinovac Stock a good investment?
Details
What is Sinovac Biotech's Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of Sinovac Biotech Correlation against competitors.
For information on how to trade Sinovac Stock refer to our How to Trade Sinovac Stock guide.
You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sinovac Biotech. If investors know Sinovac will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Sinovac Biotech assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Quarterly Earnings Growth
3.548
Earnings Share
0.971
Revenue Per Share
5.163
Quarterly Revenue Growth
3.037
Return On Assets
0.1146
Understanding Sinovac Biotech requires distinguishing between market price and book value, where the latter reflects Sinovac's accounting equity. The concept of intrinsic value - what Sinovac Biotech's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Sinovac Biotech's price substantially above or below its fundamental value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
Please note, there is a significant difference between Sinovac Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sinovac Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Sinovac Biotech's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY